Johnson & Johnson $JNJ Shares Sold by Vaughan David Investments LLC IL

Vaughan David Investments LLC IL lowered its stake in Johnson & Johnson (NYSE:JNJ) by 0.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 314,276 shares of the company’s stock after selling 2,517 shares during the quarter. Johnson & Johnson comprises about 1.4% of Vaughan David Investments LLC IL’s portfolio, making the stock its 15th biggest holding. Vaughan David Investments LLC IL’s holdings in Johnson & Johnson were worth $65,039,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently bought and sold shares of JNJ. Greenberg Financial Group acquired a new position in Johnson & Johnson in the fourth quarter valued at approximately $954,000. Varma Mutual Pension Insurance Co boosted its holdings in Johnson & Johnson by 8.9% in the third quarter. Varma Mutual Pension Insurance Co now owns 378,256 shares of the company’s stock valued at $70,136,000 after purchasing an additional 30,900 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. boosted its holdings in Johnson & Johnson by 4.3% in the third quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 5,030,835 shares of the company’s stock valued at $932,835,000 after purchasing an additional 208,765 shares in the last quarter. JT Stratford LLC boosted its holdings in Johnson & Johnson by 7.6% in the third quarter. JT Stratford LLC now owns 59,577 shares of the company’s stock valued at $11,047,000 after purchasing an additional 4,216 shares in the last quarter. Finally, World Investment Advisors boosted its holdings in Johnson & Johnson by 19.6% in the fourth quarter. World Investment Advisors now owns 161,343 shares of the company’s stock valued at $33,390,000 after purchasing an additional 26,450 shares in the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $238.59 on Friday. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.03 and a quick ratio of 0.77. The stock has a fifty day moving average price of $231.58 and a 200 day moving average price of $227.11. Johnson & Johnson has a 1-year low of $149.04 and a 1-year high of $251.71. The company has a market cap of $574.33 billion, a PE ratio of 27.58, a P/E/G ratio of 2.34 and a beta of 0.26.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, April 14th. The company reported $2.70 earnings per share for the quarter, topping the consensus estimate of $2.68 by $0.02. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.The firm had revenue of $24.06 billion during the quarter, compared to the consensus estimate of $23.60 billion. During the same period last year, the company earned $2.77 earnings per share. The company’s revenue for the quarter was up 9.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. Sell-side analysts forecast that Johnson & Johnson will post 11.57 EPS for the current year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, June 9th. Investors of record on Tuesday, May 26th were issued a dividend of $1.34 per share. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.30. This represents a $5.36 annualized dividend and a dividend yield of 2.2%. The ex-dividend date of this dividend was Tuesday, May 26th. Johnson & Johnson’s dividend payout ratio is 61.97%.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson reported encouraging late-stage results for IMAAVY (nipocalimab-aahu) in warm autoimmune hemolytic anemia, showing statistically significant durable hemoglobin response and rapid onset of effect in a disease with no FDA-approved treatment options. That supports the company’s immunology pipeline and possible future revenue growth. Article Title
• Positive Sentiment: The company expanded U.S. availability of TECNIS PureSee, an advanced cataract lens option, adding another incremental growth driver in medtech and reinforcing its leadership in eye care. Article Title
• Positive Sentiment: J&J announced plans to acquire Firefly Bio for about $1 billion, a move aimed at strengthening its cancer-treatment pipeline and signaling continued deal-making to support long-term growth. Article Title
• Positive Sentiment: Multiple analyst/commentary pieces remained constructive on JNJ’s valuation, with investors highlighting its “discount” relative to quality, strong drug profits, and AAA balance-sheet profile. Article Title
• Neutral Sentiment: Several articles reiterated that J&J remains a favored defensive dividend stock, which supports investor interest but does not change fundamentals on its own. Article Title
• Negative Sentiment: A Los Angeles jury awarded $32 million in a talc/asbestos case, renewing legal risk concerns that have long weighed on Johnson & Johnson’s shares and could keep a lid on valuation. Article Title
• Negative Sentiment: Coverage of the latest talc verdict underscores that litigation remains an important risk factor investors are still watching closely. Article Title

Analysts Set New Price Targets

A number of brokerages recently issued reports on JNJ. Citigroup upped their price target on Johnson & Johnson from $274.00 to $285.00 and gave the company a “buy” rating in a report on Tuesday, April 7th. Daiwa Securities Group increased their price objective on Johnson & Johnson from $237.00 to $246.00 and gave the company an “outperform” rating in a report on Thursday, April 16th. JPMorgan Chase & Co. increased their price objective on Johnson & Johnson from $250.00 to $260.00 and gave the company a “neutral” rating in a report on Wednesday, April 15th. TD Cowen began coverage on Johnson & Johnson in a report on Wednesday, April 8th. They issued a “buy” rating and a $250.00 price objective for the company. Finally, Rothschild & Co Redburn increased their price objective on Johnson & Johnson from $180.00 to $210.00 and gave the company a “neutral” rating in a report on Thursday, February 19th. Twenty research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $253.04.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.